Florian Ringel

Florian Ringel

Auto-generated profile, based on publicly available information

Florian Ringel

Department of Neurosurgery, LMU University Hospital, LMU Munich, Munich, Germany

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in World Neurosurgery
Verified
Journal Article
Closed access
FRFlorian Ringel
Florian Ringel
YRYu-Mi Ryang
Yu-Mi Ryang
JKJan S. Kirschke
Jan S. Kirschke
BMBirgit S. Müller
Birgit S. Müller
JWJan J. Wilkens
Jan J. Wilkens
BMBernhard Meyer
Bernhard Meyer

1 April 2017 in Journal of Cranio-Maxillofacial Surgery
Verified
Journal Article
Closed access
MKMarco Kesting
Marco Kesting
SKSteffen Koerdt
Steffen Koerdt
NRNiklas Rommel
Niklas Rommel
TMThomas Mücke
Thomas Mücke
KWKlaus-Dietrich Wolff
Klaus-Dietrich Wolff
GFGesche Frohwitter
Gesche Frohwitter

24 February 2020 in Cancers
Verified
Journal Article
Open access
PDF file
EKElla Kim
Ella Kim
Maksim SorokinMaksim Sorokin
Maksim Sorokin
Sven KantelhardtSven Kantelhardt
Sven Kantelhardt
DKDarius Kalasauskas
Darius Kalasauskas
BSBettina Sprang
Bettina Sprang
Anton BuzdinAnton Buzdin
Anton Buzdin
Background: Inevitable recurrence after radiochemotherapy is the major problem in the treatment of glioblastoma, the most prevalent type of adult brain malignancy. Glioblastomas are notorious for a high degree of intratumor heterogeneity manifest through a diversity of cell types and molecular patterns. The current paradigm of understanding glioblastoma recurrence is that cytotoxic therapy fails to target effectively glioma stem cells. Recent advances indicate that therapy-driven molecular evolution is a fundamental trait associated with glioblastoma recurrence. There is a growing body of evidence indicating that intratumor heterogeneity, longitudinal changes in molecular biomarkers and specific impacts of glioma stem cells need to be taken into consideration in order to increase the accuracy of molecular diagnostics still relying on readouts obtained from a single tumor specimen. Methods: This study integrates a multisampling strategy, longitudinal approach and complementary transcriptomic investigations in order to identify transcriptomic traits of recurrent glioblastoma in whole-tissue specimens of glioblastoma or glioblastoma stem cells. In this study, 128 tissue samples of 44 tumors including 23 first diagnosed, 19 recurrent and 2 secondary recurrent glioblastomas were analyzed along with 27 primary cultures of glioblastoma stem cells by RNA sequencing. A novel algorithm was used to quantify longitudinal changes in pathway activities and model efficacy of anti-cancer drugs based on gene expression data. Results: Our study reveals that intratumor heterogeneity of gene expression patterns is a fundamental characteristic of not only newly diagnosed but also recurrent glioblastomas. Evidence is provided that glioblastoma stem cells recapitulate intratumor heterogeneity, longitudinal transcriptomic changes and drug sensitivity patterns associated with the state of recurrence. Conclusions: Our results provide a transcriptional rationale for the lack of significant therapeutic benefit from temozolomide in patients with recurrent glioblastoma. Our findings imply that the spectrum of potentially effective drugs is likely to differ between newly diagnosed and recurrent glioblastomas and underscore the merits of glioblastoma stem cells as prognostic models for identifying alternative drugs and predicting drug response in recurrent glioblastoma. With the majority of recurrent glioblastomas being inoperable, glioblastoma stem cell models provide the means of compensating for the limited availability of recurrent glioblastoma specimens.

25 November 2020 in Cancers
Verified
Journal Article
Open access
PDF file
DKDarius Kalasauskas
Darius Kalasauskas
NKNaureen Keric
Naureen Keric
SASalman Abu Ajaj
Salman Abu Ajaj
LCLeoni von Cube
Leoni von Cube
FRFlorian Ringel
Florian Ringel
MRMirjam Renovanz
Mirjam Renovanz
The diagnosis of intracranial meningiomas as incidental findings is increasing by growing availability of MRI diagnostics. However, the psychological distress of patients with incidental meningiomas under a wait-and-watch strategy is unknown. Therefore, we aimed to compare the psychosocial situation of meningioma patients under wait-and-watch to patients after complete resection to bridge this gap. The inclusion criteria for the prospective monocenter study were either an incidental meningioma under a wait-and-watch strategy or no neurologic deficits after complete resection. Sociodemographic, clinical, and health-related quality of life and clinical data were assessed. Psychosocial factors were measured by the Distress Thermometer (DT), Hospital Anxiety and Depression Scale (HADS), Brief Fatigue Inventory (BFI), and the Short Form (SF-36). A total of 62 patients were included (n = 51 female, mean age 61 (SD 13) years). According to HADS, the prevalence of anxiety was 45% in the postoperative and 42% in the wait-and-watch group (p = 0.60), and depression was 61% and 87%, respectively (p = 0.005). In total, 43% of patients under wait-and-watch and 37% of patients in the postoperative group scored ≥6 on the DT scale. SF-36 scores were similar in all categories except general health (p = 0.005) and physical component aggregate score (43.7 (13.6) vs. 50.5 (9.5), (p = 0.03), both lower in the wait-and-watch group. Multivariate analysis revealed the wait-and-watch strategy was associated with a 4.26-fold higher risk of a pathological depression score based on HADS (p = 0.03). This study demonstrates a high prevalence of psychological distress in meningioma patients. Further evaluation is necessary to identify the patients in need of psychooncological support.

Verified
Journal Article
Open access
PDF file
NZNiklas Zimmer
Niklas Zimmer
EKElla Kim
Ella Kim
JSJonathan Schupp
Jonathan Schupp
BSBettina Sprang
Bettina Sprang
PLPetra Leukel
Petra Leukel
ATAndrea Tuettenberg
Andrea Tuettenberg
Glycoprotein A repetition predominant (GARP), a specific surface molecule of activated regulatory T cells, has been demonstrated to significantly contribute to tolerance in humans by induction of peripheral Treg and regulatory M2-macrophages and by inhibition of (tumorantigen-specific) T effector cells. Previous work identified GARP on Treg, and also GARP on the surface of several malignant tumors, as well as in a soluble form being shedded from their surface, contributing to tumor immune escape. Preliminary results also showed GARP expression on brain metastases of malignant melanoma. On the basis of these findings, we investigated whether GARP is also expressed on primary brain tumors. We showed GARP expression on glioblastoma (GB) cell lines and primary GB tissue, as well as on low-grade glioma, suggesting an important influence on the tumor micromilieu and the regulation of immune responses also in primary cerebral tumors. This was supported by the finding that GB cells led to a reduced, in part GARP-dependent effector T cell function (reduced proliferation and reduced cytokine secretion) in coculture experiments. Interestingly, GARP was localized not only on the cell surface but also in the cytoplasmatic, as well as nuclear compartments in tumor cells. Our findings reveal that GARP, as an immunoregulatory molecule, is located on, as well as in, tumor cells of GB and low-grade glioma, inhibiting effector T cell function, and thus contributing to the immunosuppressive tumor microenvironment of primary brain tumors. As GARP is expressed on activated Treg, as well as on brain tumors, it may be an interesting target for new immunotherapeutic approaches using antibody-based strategies as this indication.

1 August 2019 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
JGJulia Gerhardt
Julia Gerhardt
Nico SollmannNico Sollmann
Nico Sollmann
PHPatrick Hiepe
Patrick Hiepe
JKJan Kirschke
Jan Kirschke
BMBernhard Meyer
Bernhard Meyer
FRFlorian Ringel
Florian Ringel